Amyloidosis clinical trials
The registry lists 290 studies for Amyloidosis across more than 10 countries. 92 are recruiting or about to start. 145 of them are mainly about Amyloidosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06. Counting its 7 narrower conditions too, such as Immunoglobulin Light-chain Amyloidosis: 689 studies, 228 open.
Get an email when these change. Save the Amyloidosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Alnylam Pharmaceuticals (22) · Mayo Clinic (11) · GlaxoSmithKline (9) · Eidos Therapeutics, a BridgeBio company (8) · Fondazione IRCCS Policlinico San Matteo di Pavia (8) · Brigham and Women's Hospital (8) · Pfizer (8) · Ionis Pharmaceuticals, Inc. (8)
What is being tested here
Drugs under test in Amyloidosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Alkylating agents 1 open · Proteasome inhibitors 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis · Phase 3 · Brigham and Women's Hospital
- Mar 2027[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy · Phase 3 · Brigham and Women's Hospital
- Jul 2027A Phase 3 Study of NTLA-2001 in ATTRv-PN · Phase 3 · Intellia Therapeutics
- Nov 2026OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis · AstraZeneca
- Dec 2026Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis · Nexcella Inc.
- Dec 2026A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis · University of Tennessee Graduate School of Medicine
- Dec 2026Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study · University of Texas Southwestern Medical Center
- Dec 2026Bronx Transthyretin Amyloid Cardiomyopathy Database · Montefiore Medical Center
- Dec 2026Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis · Idoven 1903 S.L.
- Dec 2026BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis · Institute of Hematology & Blood Diseases Hospital, China
Who these studies take
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger. 7 (10%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 9 (13%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 7 (10%) | 6 (9%) |
| 18 | 61 (87%) | 60 (86%) |
| 30 | 64 (91%) | 63 (90%) |
| 40 | 66 (94%) | 65 (93%) |
| 50 | 67 (96%) | 66 (94%) |
| 65 | 70 (100%) | 69 (99%) |
| 75 | 69 (99%) | 68 (97%) |
| 85 | 56 (80%) | 55 (79%) |
Across all 290 studies, recruiting or not: 14% stop at 75 or younger and 7% at 65; 7% take children; <1% are for women only and <1% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Amyloidosis studies take
Of 25 phase 3 interventional studies under Amyloidosis, half reached primary completion within 53 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 31 mo6–58 · 18 studies | — | — |
| Phase 2 | 47 mo33–64 · 24 studies | — | — |
| Phase 3 | 53 mo40–74 · 25 studies | — | — |
| Interventional, no phase | 35 mo25–75 · 26 studies | — | — |
| Observational | 97 mo29–183 · 52 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Results posted1
- Open-Label Study of AG10 in Patients With CardiomyopathyOct 14, 2026NCT03536767
Stopped1
- Open-Label Study of AG10 in Patients With CardiomyopathyTerminatedOct 14, 2026NCT03536767
Newly registered2
- Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain AmyloidosisOct 28, 2026NCT07901725
- Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain AmyloidosisOct 14, 2026NCT07874334
Studies
Recruiting first, then most recently updated. Showing 50 of 290. Browse all 290 → or search them.
- Essen Amyloidosis RegistryRecruitingNCT068872831 country
- Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL AmyloidosisRecruitingNCT07250269Phase 11 country
- Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis DiagnosisRecruitingNCT069786605 countries
- MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)RecruitingNCT06128629Phase 326 countries
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) AmyloidosisRecruitingNCT07224672Phase 23 countries
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) AmyloidosisRecruitingNCT05652335Phase 17 countries
- PET/CT Imaging in Carriers of TTR MutationsNot yet recruitingNCT075910381 country
- Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain AmyloidosisNot yet recruitingNCT07901725Phase 3
- Prevalence of Amyloidosis in Trauma PatientsRecruitingNCT065275211 country
- Effect of Trimetazidine on Coronary Flow in Transthyretin Cardiac AmyloidosisNot yet recruitingNCT07836699Phase 21 country
- PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 LevelsNot yet recruitingNCT075385181 country
- A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyEnrolling by invitationNCT06679946Phase 317 countries
- TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With CardiomyopathyRecruitingNCT07052903Phase 336 countries
- Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain AmyloidosisNot yet recruitingNCT07874334Phase 11 country
- ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)RecruitingNCT0456151812 countries
- DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World SettingRecruitingNCT073580783 countries
- Impact of a Cardiac Rehabilitation Program on Patients With Cardiac AmyloidosisRecruitingNCT07494942Not applicable1 country
- TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With PolyneuropathyRecruitingNCT07223203Phase 322 countries
- Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance ProgramRecruitingNCT050403737 countries
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 21 country
- BE.Amycon Biobank & Data Registry UZ LeuvenRecruitingNCT071722431 country
- [18F]FIDT-10b PET Imaging in Cardiac AmyloidosisNot yet recruitingNCT07835880Phase 1/21 country
- Non-interventional Study of Patients With Transthyretin (ATTR) AmyloidosisRecruitingNCT064658106 countries
- Beta-amyloid PET/CT to Measure Potential Therapeutic Response in AL-CARecruitingNCT07829705Phase 21 country
- A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain AmyloidosisRecruitingNCT07215494Not applicable1 country
- A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFHRecruitingNCT052839931 country
- Exploratory Study Evaluating the Relevance of [68Ga]Ga-FAPI-46 for Staging and Identifying Progressing Patients With Transthyretin Cardiac AmyloidosisRecruitingNCT07549841Phase 21 country
- OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR AmyloidosisRecruitingNCT0635593411 countries
- [18F]FT8 PET Imaging in Immunoglobulin Light Chain AmyloidosisRecruitingNCT072324591 country
- Pan-Amyloid PET/CT in Various Amyloid-Related DiseaseRecruitingNCT071305651 country
- Non-Interventional Study on the Prevalence of Cardiac Amyloidosis in Patients With Higher-Grade Aortic Valve Stenosis - Evaluation Using Echocardiography, Computed Tomography, Tc99-SPECT/CT and Cardiac Magnetic Resonance Imaging (CMR)RecruitingNCT077527321 country
- Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEFRecruitingNCT05577819Not applicable1 country
- Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR CarriersRecruitingNCT054895491 country
- Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) AmyloidosisNot yet recruitingNCT07793422Phase 3
- Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL AmyloidosisRecruitingNCT05145816Phase 1/21 country
- A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL AmyloidosisNot yet recruitingNCT07765524Phase 1/21 country
- Selinexor, Daratumumab, and Dexamethasone (XDd) for Light-Chain Cardiac AmyloidosisNot yet recruitingNCT07743957Phase 2
- To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)Not yet recruitingNCT07116473Phase 3
- Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRecruitingNCT06563895Phase 324 countries
- Cardiac Magnetic Resonance and Echocardiography Study With AcoramidisRecruitingNCT07695701Phase 41 country
- A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic AmyloidosisRecruitingNCT05951816Phase 11 country
- BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed AmyloidosisRecruitingNCT07151690Phase 21 country
- Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion SystemNot yet recruitingNCT07721350Not applicable1 country
- [64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid CardiomyopathyRecruitingNCT07560306Phase 31 country
- 124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel SyndromeEnrolling by invitationNCT06907849Phase 21 country
- A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL AmyloidosisNot yet recruitingNCT07709715Phase 3
- A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.RecruitingNCT07081646Phase 1/23 countries
- Dietary Reporting In The AmyloidosesRecruitingNCT05738005Not applicable1 country
- Quantitative-imaging in Cardiac Transthyretin AmyloidosisRecruitingNCT057762121 country
- Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic StenosisRecruitingNCT04636684Not applicable1 country